PET/CT Imaging in Oncology: Exceptions That Prove the Rule

Area of Science:

• Oncology
• Nuclear Medicine
• Radiology

Background:

• (18)F-FDG PET/CT is a standard non-invasive imaging tool for assessing glucose metabolism in various diseases, particularly cancer.
• It is widely used in oncology for tumor staging, restaging, follow-up, and treatment response assessment.
• However, certain well-differentiated cancers, like clear cell renal carcinoma and bronchioloalveolar adenocarcinoma, exhibit low glucose metabolism, potentially leading to false-negative PET/CT findings.

Purpose of the Study:

• To report an extreme case of a patient with three concurrent, well-differentiated cancers.
• To illustrate the diagnostic challenge posed by multiple low-glucose metabolism malignancies.
• To highlight the limitations of (18)F-FDG PET/CT in detecting specific types of cancer.

Main Methods:

• A case report detailing a patient's diagnostic journey.
• Utilized (18)F-FDG PET/CT as the primary imaging modality.
• Correlated imaging findings with pathological diagnoses.

Main Results:

• The patient presented with three distinct, well-differentiated cancers.
• All three neoplasms demonstrated low intrinsic glucose metabolism.
• The (18)F-FDG PET/CT scan yielded a negative result, failing to detect any of the malignancies.
• This represents an extreme instance of false-negative imaging due to tumor characteristics.

Conclusions:

• (18)F-FDG PET/CT may not be sensitive for detecting all types of well-differentiated cancers, especially those with low glucose metabolism.
• The presence of multiple low-metabolism tumors in a single patient can exacerbate false-negative results.
• Clinical correlation and consideration of alternative diagnostic methods are crucial when PET/CT is negative in suspected cases of cancer.